Follow CBSMIAMI.COM: Facebook | Twitter

MIAMI (CBSMiami) – The Food and Drug Administration wants to get more generic medicines on the market as a way to make prescriptions more affordable.

Copycat pills generally have been much cheaper than original brand-name drugs. But recent high-profile cases have shown how lack of competition and medicine shortages allowed several drug companies to drastically increase prices for generics and some older brand-name products such as EpiPen emergency allergy injectors.

New FDA commissioner Dr. Scott Gottlieb made addressing prices a priority, saying that the agency can help by increasing market competition. While the FDA reviews and approves medications, it doesn’t have the power to regulate prices.

“No patient should be priced out of the medicines they need, and as an agency dedicated to promoting public health, we must do our part to help patients get access to the treatments they require,” Gottlieb said in a statement.

On Tuesday, the FDA said it will now give priority reviews to new generic drugs until there are at least three on the market. That’s the level at which prices tend to drop sharply, up to 85 percent off the brand-name price.

The agency also published its first list of brand-name drugs that no longer have a patent’s protection but don’t yet have generic competition, a strategy to entice generic drugmakers to develop copycats.

The list includes an HIV medicine, a genetically engineered heart drug, prescription multivitamins and IV salt and sugar solutions. Some have been in short supply, sometimes for years, after quality problems shut down manufacturing lines or companies stopped making them to pursue more profitable products.

Among the best-known cases of dramatic price hikes: Mylan’s fivefold increase for EpiPen’s price and former pharmaceutical executive Martin Shkreli’s Turing Pharmaceuticals raising the price of an old drug for a deadly infection more than 5,000 percent, to $750 per pill.

Meanwhile, the FDA has scheduled a July 18 meeting to discuss possible changes to its rules for approving generics, which inadvertently have enabled some makers of brand-name medicines to prevent or delay generic rivals.

Comments

Leave a Reply

Please log in using one of these methods to post your comment:

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

More From CBS Miami

Get Your Daily DoseHere's some good news just for you.
CBS4 New Home For Florida Lottery
Pro Football Challenge

Watch & Listen LIVE